PRP10: PREDICTING THE BENEFIT OF OPTIMIZING SEVERE ASTHMA MANAGEMENT IN A MANAGED CARE SETTING:A COST-BENEFIT ANALYSIS COMPARING THE COMBINATION OF FLUTICASONE PROPIONATE AND SALMETEROL (FPS) AND ZAFIRLUKAST  by Joglekar, A et al.
368 Abstracts
PRP9
THE NET COST OF ASTHMA TO NORTH
CAROLINA (NC) MEDICAID AND
IDENTIFICATION OF FACTORS DRIVING COSTS
IN AN ASTHMATIC POPULATION 
Panicker S1, Nielsen K2, Martin BC1
1University of Georgia, Athens, GA, USA; 2Global Health
Outcomes, GlaxoSmithKline, Raleigh, NC, USA
OBJECTIVE: To estimate the net cost of asthma to NC
Medicaid and identify factors inﬂuencing the health care
cost of asthmatics. METHODS: The study design was a
retrospective matched case control design wherein admin-
istrative claims data from NC Medicaid spanning May
1996 through April 1998 were utilized. Inclusion criteria
were: at least one inpatient claim for asthma (ICD-9-CM
= 493) or 2 or more outpatient asthma claims or asthma
prescriptions in the ﬁrst year. Exclusion criteria were: a
diagnosis for emphysema, COPD, cancer, age <1 and age
>65, a nursing home claim, or prescription for Iprat-
ropium in the ﬁrst year. A sensitivity analysis using case
deﬁnitions restricted to diagnosis or drug markers was
also undertaken. To estimate net costs, non-asthmatic
comparison subjects were matched 1 :1 on age, gender,
and race. Net adjusted cost differences were obtained
from a generalized least square (GLS) model accounting
for heteroscedasticity with terms to account for
unmatched factors. To investigate factors inﬂuencing
asthma costs, separate GLS models exploring 40 differ-
ent comorbidity categories, demographics were estimated
for all asthmatics. RESULTS: The net cost for asthma was
$910 (CI: 787 to 1032, N = 27,493) with prescriptions
(33%), hospitalizations (14%) comprising a majority of
costs. The net cost of asthma was not meaningfully
affected by varying case deﬁnitions but prevalence esti-
mates varied between 2.2% to 4.6%. In the asthma
group, asthmatics with congestive heart failure ($3232),
psychoses ($3128), diabetes ($2143), depression ($1363),
and lower respiratory tract infections ($416) were among
the most inﬂuential comorbidity drivers of total cost (p <
0.001). Males ($486) and whites ($835) had higher costs
than their counterparts (p < 0.001). For prescription and
physician costs, diseases such as hypertension, rhinitis,
and sinusitis were also inﬂuential (p < 0.001). CON-
CLUSION: The net cost of asthma is estimated at
$900/year above a comparable non-asthmatic Medicaid
recipient. The cost of asthma is driven by prescriptions,
hospitalizations and is greatly affected by several comor-
bidities which should be considered when delivering care
for asthmatics.
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PREDICTING THE BENEFIT OF OPTIMIZING
SEVERE ASTHMA MANAGEMENT IN A
MANAGED CARE SETTING:A COST-BENEFIT
ANALYSIS COMPARING THE COMBINATION OF
FLUTICASONE PROPIONATE AND
SALMETEROL (FPS) AND ZAFIRLUKAST 
Joglekar A, Chao C, Kadison P
Medical Scientists, Inc, Boston, MA, USA
OBJECTIVES: The combination drug, ﬂuticasone propi-
onate and salmeterol (FPS), and zaﬁrlukast, a leukotriene
receptor antagonist (LTRA), represent two classes of
asthma controller medications. FPS has been shown to be
more clinically effective compared to drugs in the LTRA
group. Our objective is to determine the ﬁnancial bene-
ﬁts associated with managing severe adult asthma with
FPS or zaﬁrlukast, from a self-insured employer’s per-
spective. METHODS: We developed a Markov model 
to predict the health outcomes and costs for asthma in a
hypothetical, commercially insured population. The
model predicts asthma costs of hospitalizations, phar-
macy, professional visits, and outpatient services. It also
estimates non-medical costs using lost workdays due to
asthma. We used $2.40 as the plan’s net cost per patient
per day for FPS and $1.48 for zaﬁrlukast. The beneﬁcial
effects of each drug are modeled by a reduction in health
service utilization and lost workdays. The model assumes
that all severe adult asthma patients not well managed 
at baseline are optimally managed in the intervention 
scenario, with 100% medication compliance. The cost-
beneﬁt is expressed as net savings in medical and non-
medical costs. RESULTS: For a commercially insured
population of 100,000 members, the model predicted 276
severe adult asthma cases, and net savings of $0.13 per
member per month (PMPM) over 3 years for FPS. Zaﬁr-
lukast is estimated to take more than three years to break
even. For both drugs, about 46% of total savings are
from non-medical savings. A sensitivity analysis shows
that FPS continues to be cost beneﬁcial over 3 years as
long as the medication compliance is 63% or more.
CONCLUSIONS: Managing adult severe asthma with
FPS is predicted to be cost-beneﬁcial in the short term
from a self-insured employer’s perspective.
PRP11
CHANGES IN ASTHMA-RELATED HEALTHCARE
UTILIZATION AND COSTS AFTER THE
ADDITION OF SALMETEROL TO A MEDICAID
POPULATION
Shah BM, Dodd MA, Gupchup GV, Kelly HW
The University of New Mexico, Albuquerque, NM, USA
OBJECTIVE: To determine whether the introduction of
salmeterol to a population of low-income, moderate 
to severe asthmatics can reduce overall asthma-related
healthcare costs and utilization. METHODS: A Medicaid
fee-for-service database with prescription, outpatient and
